484 related articles for article (PubMed ID: 16838223)
1. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.
Ullmann AJ; Sanz MA; Tramarin A; Barnes RA; Wu W; Gerlach BA; Krobot KJ; Gerth WC;
Clin Infect Dis; 2006 Aug; 43(4):e29-38. PubMed ID: 16838223
[TBL] [Abstract][Full Text] [Related]
2. Nephrotoxicity in the setting of invasive fungal diseases.
Ullmann AJ
Mycoses; 2008; 51 Suppl 1():25-30. PubMed ID: 18471158
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan.
Chen CY; Kumar RN; Feng YH; Ho CH; You JY; Liao CC; Tseng CH; Mavros P; Gerth WC; Chen YC
J Antimicrob Chemother; 2006 Jun; 57(6):1181-8. PubMed ID: 16595642
[TBL] [Abstract][Full Text] [Related]
4. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
5. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
Maharom P; Thamlikitkul V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
[TBL] [Abstract][Full Text] [Related]
6. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.
Miller CB; Waller EK; Klingemann HG; Dignani MC; Anaissie EJ; Cagnoni PJ; McSweeney P; Fleck PR; Fruchtman SM; McGuirk J; Chao NJ
Bone Marrow Transplant; 2004 Mar; 33(5):543-8. PubMed ID: 14730342
[TBL] [Abstract][Full Text] [Related]
7. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
Aguado JM; Lumbreras C; González-Vidal D;
Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
[TBL] [Abstract][Full Text] [Related]
8. [Safety of liposomal amphotericin B in patients with high risk of nephrotoxicity].
González E; Rada MA; Lumbreras C; Ramos JT; Aguado JM
Enferm Infecc Microbiol Clin; 2000 Apr; 18(4):162-4. PubMed ID: 10932392
[TBL] [Abstract][Full Text] [Related]
9. Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.
Garbino J; Markham L; Matulionyte R; Rives V; Lew D
Scand J Infect Dis; 2006; 38(2):110-3. PubMed ID: 16449001
[TBL] [Abstract][Full Text] [Related]
10. Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients.
Noskin G; Pietrelli L; Gurwith M; Bowden R
Bone Marrow Transplant; 1999 Apr; 23(7):697-703. PubMed ID: 10218847
[TBL] [Abstract][Full Text] [Related]
11. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
Alvarez-Lerma F; Soriano MC; Rodríguez M; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maraví E; Fernández E; Alvarado F; López M; Alvarez-Sánchez B; Espinosa J; Quintana E;
Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
[TBL] [Abstract][Full Text] [Related]
12. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
Viscoli C; Castagnola E
Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
[TBL] [Abstract][Full Text] [Related]
13. Proteinuria lowers the risk of amphotericin B-associated hypokalaemia.
Mohan S; Ahmed S; Alimohammadi B; Jaitly M; Cheng JT; Pogue VA
J Antimicrob Chemother; 2007 Sep; 60(3):690-3. PubMed ID: 17597057
[TBL] [Abstract][Full Text] [Related]
14. Study of renal safety in amphotericin B lipid complex-treated patients.
Alexander BD; Wingard JR
Clin Infect Dis; 2005 May; 40 Suppl 6():S414-21. PubMed ID: 15809928
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.
Wingard JR; Kubilis P; Lee L; Yee G; White M; Walshe L; Bowden R; Anaissie E; Hiemenz J; Lister J
Clin Infect Dis; 1999 Dec; 29(6):1402-7. PubMed ID: 10585786
[TBL] [Abstract][Full Text] [Related]
16. [Safety of long-term administration of conventional amphotericin B in oncology patients].
Doubek M; Mayer J; Horký D
Cas Lek Cesk; 2002 Mar; 141(5):156-9. PubMed ID: 11998223
[TBL] [Abstract][Full Text] [Related]
17. [Impact on renal function of an early switch from conventional to liposomal amphotericin B formulation in the empirical treatment of fungal infections].
Isnard F; Tilleul P; Laporte JP; Chevallier P; Pigneux A; Lafuma A; Monchecourt F; Mahi L; Deray G
Med Mal Infect; 2008 Apr; 38(4):208-14. PubMed ID: 18191521
[TBL] [Abstract][Full Text] [Related]
18. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Ullmann AJ; Bouza E; Heussel CP; Lortholary O; Rieger C; Boehme A; Aoun M; Horst HA; Thiebaut A; Ruhnke M; Reichert D; Vianelli N; Krause SW; Olavarria E; Herbrecht R;
Clin Infect Dis; 2007 May; 44(10):1289-97. PubMed ID: 17443465
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of the use of liposomal amphotericin B].
González Martínez M; Mariño Martínez C; Baldominos Utrilla G; Fernández Martínez MN
Rev Iberoam Micol; 2014; 31(2):109-13. PubMed ID: 23711815
[TBL] [Abstract][Full Text] [Related]
20. [Must we be really concerned about amphotericin B toxicity in oncology patients?].
Mayer J; Doubek M
Cas Lek Cesk; 1998 Oct; 137(20):632-6. PubMed ID: 9863267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
